Patents by Inventor Li-Tzu Chen

Li-Tzu Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTAGONISTS
    Publication number: 20220049017
    Abstract: The invention relates to Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) antagonists, such as antibodies and fragments, as well as methods, uses and combinations.
    Type: Application
    Filed: December 18, 2019
    Publication date: February 17, 2022
    Inventors: Allan BRADLEY, Qi LIANG, E-Chiang LEE, Li-Ying LIOU, Yu-Hui HUANG, Yen-Ju CHEN, Li-Tzu CHEN
  • Methods for glycoprotein remodeling using endoglycosidase mutants
    Patent number: 10407673
    Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: September 10, 2019
    Assignees: CHO Pharma Inc., Academia Sinica
    Inventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
  • ENDOGLYCOSIDASE MUTANTS FOR GLYCOPROTEIN REMODELING AND METHODS OF USING IT
    Publication number: 20180298361
    Abstract: A mutant of Endos2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 18, 2018
    Applicants: Academia Sinica
    Inventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S. Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
  • Endoglycosidase mutants for glycoprotein remodeling and methods of using it
    Patent number: 10000747
    Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 19, 2018
    Assignees: Academia Sinica, CHO Pharma Inc.
    Inventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
  • ENDOGLYCOSIDASE MUTANTS FOR GLYCOPROTEIN REMODELING AND METHODS OF USING IT
    Publication number: 20180057804
    Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 1, 2018
    Applicants: CHO Pharma Inc., Academia Sinica
    Inventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng